Head-to-Head Comparison of All Botulinum Neurotoxin Type A Products for Glabellar Rhytides

计划入组 325 人 · 首次发布于 2024 年 6 月 7 日

Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)

计划入组 43 人 · 首次发布于 2024 年 8 月 26 日

Sarcopenia and Osteopenia in Individuals With Cerebral Palsy and Influences After Botulinum Neurotoxin Type A Injection

计划入组 60 人 · 首次发布于 2022 年 1 月 26 日

Recombinant botulinum neurotoxin type A(Chongqing Claruvis)

Clostridium botulinum

Equine Botulinum Neurotoxin A Immune FAB2(BAT)

A&A SMALL CHANGES HANDYPEOPLE

United States

Novozymes A/S

Denmark

Ambu A/S

Denmark

Combined IPL and Botulinum Toxin Shows Promise in Treating Rosacea, Latin American Study Finds

Merz Therapeutics Wins EU/EEA Approval for Xeomin in Pediatric Pes Equinus Spasticity

Dysport Becomes First Botulinum Toxin to Achieve Positive Phase III Results in Both Episodic and Chronic Migraine